Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant Long-Term Safety Extension in Episodic Migraine
NCT03939312Phase 3Completed
- Sponsor
- Allergan
- Start
- May 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atogepant in episodic migraine, sponsored by Allergan. Primary endpoint: Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event at Week 44. Started May 2019; status: completed.
02
Drugs
atogepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT03939312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939312.